FDA needs three more months to re­view Roche's SMA drug — giv­ing Bio­gen, No­var­tis some re­lief

The first oral drug for spinal mus­cu­lar at­ro­phy was wide­ly ex­pect­ed to be ap­proved by the end of May af­ter pri­or­i­ty re­view. But its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.